Introduction:

Tolvaptan introduction has constituted the main therapeutic novelty in the management of hyponatremia in recent years.

Objective:

To describe the experience with this drug at Complejo Asistencial Universitario de León, Spain.

Method:

Retrospective, observational study of tolvaptan outpatient use in a tertiary care hospital from March 2014 to August 2017.

Results:

A total of 9 patients were treated with tolvaptan in the outpatient setting. Eunatremia was reached in 24 h by 23.1%. After tolvaptan administration, a reduction in days of hospitalization was recorded (361 vs. 70; p = 0.007), especially in those days of hospitalization that were attributable to hyponatremia (306 vs. 49; p = 0.009).

Conclusions:

Long-term use of tolvaptan appears to be safe and is associated with a decrease in days of hospitalization.